Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

TACI (human):Fc (human), (recombinant)

 
ALX-522-033-C050 50 µg 383.00 USD
Do you need bulk/larger quantities?
 

Product Specification

Alternative Name:TNFRSF 13B, Transmembrane activator and CAML interactor, CD267
 
MW:~40kDa (SDS-PAGE)
 
Source:Produced in HEK 293 cells. The extracellular domain of human TACI (aa 2-118) is fused to the Fc portion of human IgG1.
 
UniProt ID:O14836
 
Concentration:1mg/ml after reconstitution.
 
Formulation:Lyophilized. Contains PBS.
 
Purity:≥95% (SDS-PAGE)
 
Endotoxin Content:<0.1EU/µg purified protein (LAL test; BioWhittaker).
 
Species reactivity:Human, Mouse
 
Specificity:Binds human and mouse (weak) BAFF and APRIL.
 
Reconstitution:Reconstitute with 50µl sterile water. Further dilutions should be made with medium containing 5% fetal calf serum.
 
Shipping:Shipped on Blue Ice
 
Long Term Storage:-20°C
 
Use/Stability:Stable for at least 6 months after receipt when stored at -20°C.
 
Handling:Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -20°C.
 
Scientific Background:TACI (transmembrane activator and CAML-interactor) is a 40kDa protein which belongs to the tumor necrosis factor (TNF) receptor family. TACI specifically binds to BAFF and APRIL, two members of the TNF family. Activation of TACI induces recruitment of TNF-R-associated factors (TRAF)-2, -5 and -6 leading to the activation of NFκB, NF-AT and AP1. APRIL and BAFF induce proliferation and IgM secretion. BAFF is involved in the onset of Systemic Lupus Erythematosus (SLE) in mice. Historical data has shown that TACI blocks the binding of BAFF and APRIL to their receptors BCMA and TACI, inhibiting BAFF-mediated B cell activation.
 
522-033
Inhibition of BAFF-mediated B cell activation:

Figure: rhTACI:Fc inhibits BAFF-mediated activation of freshly isolated B cells. Concentration of rhTACI:Fc to achieve complete inhibition depends on the concentration of rhsBAFF (Prod. No. ALX-522-025) used. Normally a ratio (rhsBAFF:rhTACI:Fc) 1:20 to 1:50 should be used. Y axis shows the % of B cells alive.

Method: Splenocytes were isolated from a freshly collected spleen. An aliquot of the splenocytes was analyzed by FACS, and B cells were gated on the SSC-FSC panel (column A, 20.05% alive B cells). FACS settings were saved. The rest of the cells was put in culture with media alone (B), with 2 mg/ml rhsBAFF (C) or with 2 mg/ml rhsBAFF and an excess of rhTACI:Fc (D, +4 mg/ml ; E, +20mg/ml; F, +100mg/ml). After three days in culture, cells were again analyzed by FACS with the saved setting, and % of B cells that survived was calculated: A 20.05%, B 2.58%, C 20.60%, D 17.61%, E 10.07%, F 4.92%.

Please mouse over
522-033

Product Literature References

APRIL and BAFF promote increased viability of replicating human B2 cells via mechanism involving cyclooxygenase 2: P.K. Mongini, et al.; J. Immunol. 176, 6736 (2006), Abstract;
BAFF production by antigen-presenting cells provides T cell co-stimulation: B. Huard, et al.; Int. Immunol. 16, 467 (2004), Abstract;
Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL: B. He, et al.; J. Immunol. 172, 3268 (2004), Abstract; Full Text
Potential role of APRIL as autocrine growth factor for megakaryocytopoiesis: D. Bonci, et al.; Blood 103, 3169 (2004), Abstract; Full Text
Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen: P. Schneider, et al.; J. Exp. Med. 194, 1691 (2001), Abstract;
T cell costimulation by the TNF ligand BAFF: B. Huard, et al.; J. Immunol. 167, 6225 (2001), Abstract;

General Literature References

A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth: P. Rennert, et al.; J. Exp. Med. 192, 1677 (2000), Abstract;
Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI: S.A. Marsters, et al.; Curr. Biol. 10, 785 (2000), Abstract;
TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease: J.A. Gross, et al.; Nature 404, 995 (2000), Abstract;
TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation: X.Z. Xia, et al.; J. Exp. Med. 192, 137 (2000), Abstract;
Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS: Y. Wu, et al.; J. Biol. Chem. 275, 35478 (2000), Abstract;
NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily: G.U. von Bulow & R.J. Bram; Science 278, 138 (1997), Abstract;

Related Products

Control:Fc fusion protein (human), (recombinant) 

Negative control for Fc chimeric proteins
Produced in HEK 293 cells. The extracellular domain of mutated hThy-1, hThy-1 (RLE) (aa 20-130), is fused to the Fc portion of human IgG1. The integrin binding sequence RLD of hThy-1 has been changed to RLE abolishing the binding of integrins., ≥90% (SDS-PAGE) | Print as PDF
 
ALX-203-004-C050 50 µg 405.00 USD
Do you need bulk/larger quantities?
 

Product Toolbox

PRODUCT RESOURCES

Datasheet
MSDS
Certificate of Analysis

RELATED PRODUCTS

By target:
TACI
By biological activity:
TACI Recombinant protein
By catalog section:

PRODUCT SUPPORT

FAQs
Technical Service
Customer Service

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,